Atherosclerosis is a major contributor to cardiovascular disease, characterized by inflammation and lipid accumulation in arterial walls, leading to plaque formation. Elevated low-density lipoprotein cholesterol is a primary risk factor for atherosclerosis. All-trans retinoic acid (ATRA), a metabolite of vitamin A, has demonstrated anti-inflammatory effects and potential in regulating vascular injury. 9-cisretinoic acid (9cRA) is an active metabolite of vitamin A and activates the retinoid X receptor. This study investigates whether potassium retinoate (PA9RA), a synthetic combination of ATRA and 9cRA, offers superior efficacy in treating atherosclerosis compared to established treatments such as clopidogrel and atorvastatin. Male ApoE -/- mice were fed a Western-type diet and treated with PA9RA, clopidogrel, or atorvastatin for 10 weeks. The body weight, organ weight, serum biochemistry, and histopathology, including atherosclerotic lesion area and liver steatosis were assessed. PA9RA treatment led to a significant reduction in body weight and inguinal fat, with the 45 mg/kg/day dose showing marked efficacy in decreasing atherosclerotic lesion size and ameliorating liver steatosis. Histopathological evaluation revealed decreased foam cell formation and improved liver histology in PA9RA-treated groups compared to controls. Notable side effects included epidermal hyperplasia and gastric hyperplasia at high doses of PA9RA. PA9RA exhibits superior efficacy over clopidogrel and atorvastatin in ameliorating atherosclerosis and fatty liver in ApoE –/–mice. This study highlights PA9RA's potential as a promising therapeutic agent for atherosclerosis. Further research is needed to elucidate its mechanisms of action and assess long-term safety and efficacy.

Atherosclerosis is a major contributor to cardiovascular disease, characterized by inflammation and lipid accumulation in arterial walls, leading to plaque formation. Elevated low-density lipoprotein cholesterol is a primary risk factor for atherosclerosis. All-trans retinoic acid (ATRA), a metabolite of vitamin A, has demonstrated anti-inflammatory effects and potential in regulating vascular injury. 9-cisretinoic acid (9cRA) is an active metabolite of vitamin A and activates the retinoid X receptor. This study investigates whether potassium retinoate (PA9RA), a synthetic combination of ATRA and 9cRA, offers superior efficacy in treating atherosclerosis compared to established treatments such as clopidogrel and atorvastatin. Male ApoE -/- mice were fed a Western-type diet and treated with PA9RA, clopidogrel, or atorvastatin for 10 weeks. The body weight, organ weight, serum biochemistry, and histopathology, including atherosclerotic lesion area and liver steatosis were assessed. PA9RA treatment led to a significant reduction in body weight and inguinal fat, with the 45 mg/kg/day dose showing marked efficacy in decreasing atherosclerotic lesion size and ameliorating liver steatosis. Histopathological evaluation revealed decreased foam cell formation and improved liver histology in PA9RA-treated groups compared to controls. Notable side effects included epidermal hyperplasia and gastric hyperplasia at high doses of PA9RA. PA9RA exhibits superior efficacy over clopidogrel and atorvastatin in ameliorating atherosclerosis and fatty liver in ApoE –/–mice. This study highlights PA9RA's potential as a promising therapeutic agent for atherosclerosis. Further research is needed to elucidate its mechanisms of action and assess long-term safety and efficacy.

Atherosclerosis is a major contributor to cardiovascular disease, characterized by inflammation and lipid accumulation in arterial walls, leading to plaque formation. Elevated low-density lipoprotein cholesterol is a primary risk factor for atherosclerosis. All-trans retinoic acid (ATRA), a metabolite of vitamin A, has demonstrated anti-inflammatory effects and potential in regulating vascular injury. 9-cisretinoic acid (9cRA) is an active metabolite of vitamin A and activates the retinoid X receptor. This study investigates whether potassium retinoate (PA9RA), a synthetic combination of ATRA and 9cRA, offers superior efficacy in treating atherosclerosis compared to established treatments such as clopidogrel and atorvastatin. Male ApoE -/- mice were fed a Western-type diet and treated with PA9RA, clopidogrel, or atorvastatin for 10 weeks. The body weight, organ weight, serum biochemistry, and histopathology, including atherosclerotic lesion area and liver steatosis were assessed. PA9RA treatment led to a significant reduction in body weight and inguinal fat, with the 45 mg/kg/day dose showing marked efficacy in decreasing atherosclerotic lesion size and ameliorating liver steatosis. Histopathological evaluation revealed decreased foam cell formation and improved liver histology in PA9RA-treated groups compared to controls. Notable side effects included epidermal hyperplasia and gastric hyperplasia at high doses of PA9RA. PA9RA exhibits superior efficacy over clopidogrel and atorvastatin in ameliorating atherosclerosis and fatty liver in ApoE –/–mice. This study highlights PA9RA's potential as a promising therapeutic agent for atherosclerosis. Further research is needed to elucidate its mechanisms of action and assess long-term safety and efficacy.

Atherosclerosis is a major contributor to cardiovascular disease, characterized by inflammation and lipid accumulation in arterial walls, leading to plaque formation. Elevated low-density lipoprotein cholesterol is a primary risk factor for atherosclerosis. All-trans retinoic acid (ATRA), a metabolite of vitamin A, has demonstrated anti-inflammatory effects and potential in regulating vascular injury. 9-cisretinoic acid (9cRA) is an active metabolite of vitamin A and activates the retinoid X receptor. This study investigates whether potassium retinoate (PA9RA), a synthetic combination of ATRA and 9cRA, offers superior efficacy in treating atherosclerosis compared to established treatments such as clopidogrel and atorvastatin. Male ApoE -/- mice were fed a Western-type diet and treated with PA9RA, clopidogrel, or atorvastatin for 10 weeks. The body weight, organ weight, serum biochemistry, and histopathology, including atherosclerotic lesion area and liver steatosis were assessed. PA9RA treatment led to a significant reduction in body weight and inguinal fat, with the 45 mg/kg/day dose showing marked efficacy in decreasing atherosclerotic lesion size and ameliorating liver steatosis. Histopathological evaluation revealed decreased foam cell formation and improved liver histology in PA9RA-treated groups compared to controls. Notable side effects included epidermal hyperplasia and gastric hyperplasia at high doses of PA9RA. PA9RA exhibits superior efficacy over clopidogrel and atorvastatin in ameliorating atherosclerosis and fatty liver in ApoE –/–mice. This study highlights PA9RA's potential as a promising therapeutic agent for atherosclerosis. Further research is needed to elucidate its mechanisms of action and assess long-term safety and efficacy.

This report presents the case of severe tooth wear and vertical dimension loss in a 71-year-old male patient. A combined conventional and digital approach was employed for full-mouth rehabilitation. After determining an increase in the vertical dimension of 5.5 mm using an anterior jig and diagnostic wax-up, provisional restorations were fabricated and adjusted throughout the adaptation period.For the fabrication of the final prosthesis, digital methodologies such as oral scanning and occlusal acquisition were performed. To obtain precise margin data, a die model was fabricated using the traditional impression method, followed by model scanning, which was then combined with intraoral scan data. The final prosthesis was made of zirconia to enhance esthetics and strength. Consequently, the treatment enhanced both function and esthetics, leading to high patient satisfaction with the outcomes.

Atherosclerosis is a major contributor to cardiovascular disease, characterized by inflammation and lipid accumulation in arterial walls, leading to plaque formation. Elevated low-density lipoprotein cholesterol is a primary risk factor for atherosclerosis. All-trans retinoic acid (ATRA), a metabolite of vitamin A, has demonstrated anti-inflammatory effects and potential in regulating vascular injury. 9-cisretinoic acid (9cRA) is an active metabolite of vitamin A and activates the retinoid X receptor. This study investigates whether potassium retinoate (PA9RA), a synthetic combination of ATRA and 9cRA, offers superior efficacy in treating atherosclerosis compared to established treatments such as clopidogrel and atorvastatin. Male ApoE -/- mice were fed a Western-type diet and treated with PA9RA, clopidogrel, or atorvastatin for 10 weeks. The body weight, organ weight, serum biochemistry, and histopathology, including atherosclerotic lesion area and liver steatosis were assessed. PA9RA treatment led to a significant reduction in body weight and inguinal fat, with the 45 mg/kg/day dose showing marked efficacy in decreasing atherosclerotic lesion size and ameliorating liver steatosis. Histopathological evaluation revealed decreased foam cell formation and improved liver histology in PA9RA-treated groups compared to controls. Notable side effects included epidermal hyperplasia and gastric hyperplasia at high doses of PA9RA. PA9RA exhibits superior efficacy over clopidogrel and atorvastatin in ameliorating atherosclerosis and fatty liver in ApoE –/–mice. This study highlights PA9RA's potential as a promising therapeutic agent for atherosclerosis. Further research is needed to elucidate its mechanisms of action and assess long-term safety and efficacy.

BACKGROUND/OBJECTIVES: The increasing prevalence of overweight and obesity has become a significant global burden, with more than 40% of the global adult population attempting to lose weight. Previous studies on the impact of weight-control methods on mental health, especially among adolescents, are limited. Thus, this study aimed to investigate the association between various weight-control methods and depression among adolescents, with the goal of informing healthier weight management decisions and promoting effective methods. SUBJECTS/METHODS: This nationwide study utilized data from the Korea Youth Risk Behavior Web-based Survey, including a sample of 418,254 adolescents collected over 12yrs (2007–2019). We conducted a weighted complex sample analysis to compare depression rates associated with specific weight-control methods, including exercise, fasting (≥ 24 h), eating less, taking prescriptionon-prescription weight-loss medication, taking laxatives or diuretics, vomiting, one-food diet, taking oriental medicine, and diet foods. RESULTS: Of the 418,254 participants, 45.96% (192,246) were male. Among male participants, fasting (≥ 24 h; weighted odds ratio [wOR], 1.43; 95% confidence interval [CI], 1.36–1.51) and vomiting (wOR, 1.49; 95% CI, 1.35–1.66) were associated with an increased risk of depression. Among female participants, prescribed (wOR, 0.82; 95% CI, 0.74–0.90) and non-prescribed (wOR, 0.89; 95% CI, 0.82–0.97) weight-loss medication reduced the risk of depression. However, fasting (≥ 24 h; wOR, 1.47; 95% CI, 1.41–1.52) vomiting (wOR, 1.45;95% CI, 1.36–1.55) significantly increased the risk of depression. CONCLUSION The risk of depression varies depending on the weight-control method, with a consistent trend observed across both sexes. Methods such as vomiting, fasting, taking oriental medicine for weight loss, and consuming diet foods increased the risk of depression, while weight-loss medications were associated with reduced depression symptoms in females. These findings highlight the need for further research on weightcontrol medications and policies that support effective weight management while reducing depressive effects.

BACKGROUND/OBJECTIVES: The increasing prevalence of overweight and obesity has become a significant global burden, with more than 40% of the global adult population attempting to lose weight. Previous studies on the impact of weight-control methods on mental health, especially among adolescents, are limited. Thus, this study aimed to investigate the association between various weight-control methods and depression among adolescents, with the goal of informing healthier weight management decisions and promoting effective methods. SUBJECTS/METHODS: This nationwide study utilized data from the Korea Youth Risk Behavior Web-based Survey, including a sample of 418,254 adolescents collected over 12yrs (2007–2019). We conducted a weighted complex sample analysis to compare depression rates associated with specific weight-control methods, including exercise, fasting (≥ 24 h), eating less, taking prescriptionon-prescription weight-loss medication, taking laxatives or diuretics, vomiting, one-food diet, taking oriental medicine, and diet foods. RESULTS: Of the 418,254 participants, 45.96% (192,246) were male. Among male participants, fasting (≥ 24 h; weighted odds ratio [wOR], 1.43; 95% confidence interval [CI], 1.36–1.51) and vomiting (wOR, 1.49; 95% CI, 1.35–1.66) were associated with an increased risk of depression. Among female participants, prescribed (wOR, 0.82; 95% CI, 0.74–0.90) and non-prescribed (wOR, 0.89; 95% CI, 0.82–0.97) weight-loss medication reduced the risk of depression. However, fasting (≥ 24 h; wOR, 1.47; 95% CI, 1.41–1.52) vomiting (wOR, 1.45;95% CI, 1.36–1.55) significantly increased the risk of depression. CONCLUSION The risk of depression varies depending on the weight-control method, with a consistent trend observed across both sexes. Methods such as vomiting, fasting, taking oriental medicine for weight loss, and consuming diet foods increased the risk of depression, while weight-loss medications were associated with reduced depression symptoms in females. These findings highlight the need for further research on weightcontrol medications and policies that support effective weight management while reducing depressive effects.

BACKGROUND/OBJECTIVES: The increasing prevalence of overweight and obesity has become a significant global burden, with more than 40% of the global adult population attempting to lose weight. Previous studies on the impact of weight-control methods on mental health, especially among adolescents, are limited. Thus, this study aimed to investigate the association between various weight-control methods and depression among adolescents, with the goal of informing healthier weight management decisions and promoting effective methods. SUBJECTS/METHODS: This nationwide study utilized data from the Korea Youth Risk Behavior Web-based Survey, including a sample of 418,254 adolescents collected over 12yrs (2007–2019). We conducted a weighted complex sample analysis to compare depression rates associated with specific weight-control methods, including exercise, fasting (≥ 24 h), eating less, taking prescriptionon-prescription weight-loss medication, taking laxatives or diuretics, vomiting, one-food diet, taking oriental medicine, and diet foods. RESULTS: Of the 418,254 participants, 45.96% (192,246) were male. Among male participants, fasting (≥ 24 h; weighted odds ratio [wOR], 1.43; 95% confidence interval [CI], 1.36–1.51) and vomiting (wOR, 1.49; 95% CI, 1.35–1.66) were associated with an increased risk of depression. Among female participants, prescribed (wOR, 0.82; 95% CI, 0.74–0.90) and non-prescribed (wOR, 0.89; 95% CI, 0.82–0.97) weight-loss medication reduced the risk of depression. However, fasting (≥ 24 h; wOR, 1.47; 95% CI, 1.41–1.52) vomiting (wOR, 1.45;95% CI, 1.36–1.55) significantly increased the risk of depression. CONCLUSION The risk of depression varies depending on the weight-control method, with a consistent trend observed across both sexes. Methods such as vomiting, fasting, taking oriental medicine for weight loss, and consuming diet foods increased the risk of depression, while weight-loss medications were associated with reduced depression symptoms in females. These findings highlight the need for further research on weightcontrol medications and policies that support effective weight management while reducing depressive effects.

Satellite glial cells (SGCs), a major type of glial cell in the autonomic ganglia, closely envelop the cell body and even the synaptic regions of a single neuron with a very narrow gap. This structurally unique organization suggests that autonomic neurons and SGCs may communicate reciprocally. Glial Ca2+ signaling is critical for controlling neural activity. Here, for the first time we identified the machinery of store-operated Ca2+ entry (SOCE) which is critical for cellular Ca2+ homeostasis in rat sympathetic ganglia under normal and pathological states. Quantitative realtime PCR and immunostaining analyses showed that Orai1 and stromal interaction molecules 1 (STIM1) proteins are the primary components of SOCE machinery in the sympathetic ganglia. When the internal Ca2+ stores were depleted in the absence of extracellular Ca2+ , the number of plasmalemmal Orai1 puncta was increased in neurons and SGCs, suggesting activation of the Ca2+ entry channels. Intracellular Ca2+imaging revealed that SOCE was present in SGCs and neurons; however, the magnitude of SOCE was much larger in the SGCs than in the neurons. The SOCE was significantly suppressed by GSK7975A, a selective Orai1 blocker, and Pyr6, a SOCE blocker.Lipopolysaccharide (LPS) upregulated the glial fibrillary acidic protein and Toll-like receptor 4 in the sympathetic ganglia. Importantly, LPS attenuated SOCE via downregulating Orai1 and STIM1 expression. In conclusion, sympathetic SGCs functionally express the SOCE machinery, which is indispensable for intracellular Ca2+ signaling.The SOCE is highly susceptible to inflammation, which may affect sympathetic neuronal activity and thereby autonomic output.